All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ acute lymphoblastic leukemia?

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Philadelphia-positive (Ph+) ALL?

Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?

Short presents promising safety and efficacy data from a single-arm phase II study investigating a combination of ponatinib + blinatumomab, in adult patients with newly diagnosed or relapsed/refractory Ph+ ALL

 

Share: